March 26, 2022
1 minute read
Freedle K, et al. Attach. Impact of chronic spontaneous urticaria on health-related quality of life in the United States. Presented at the American Academy of Dermatology Annual Meeting; March 25-29, 2022; Boston.
Freedle declares to be an employee of Novartis Pharmaceuticals. Please see the study for relevant financial information from all other authors.
BOSTON – Chronic spontaneous urticaria negatively impacts patients’ lives, including mental and physical health and daily activities, according to a poster presented at the annual meeting of the American Academy of Dermatology.
“Previous research has demonstrated that chronic spontaneous urticaria (CSU) negatively impacts health-related quality of life (HRQoL), including work productivity and activity impairment (WPAI)” , Karine freedledoctor, of Novartis Pharmaceuticals Corporation, and colleagues wrote.
This survey study of 635 CSU patients found that 77% had poorly controlled disease. The average Dermatology Quality of Life Index score was 13.76, with 54.2% of patients reporting a DLQI score below 10. Mental health scores were also lower.
The mean General Anxiety Disorder-7 score was 10.55 and the mean Patient Health Questionnaire-9 score was 13.54, with 54.8% of patients reporting moderate or severe anxiety and 62% patients reporting moderate or severe depression.
The average work absenteeism rate was 36.5% and the overall work incapacity had an average of 73.1%.
“This real-world patient-reported observational study reveals that UHC has a substantial humanistic burden for patients with active disease,” the authors wrote. “The majority of CSU patients had poor disease control, reported high impact on mental and physical health, and impaired work and daily activities.”